OTCMKTS:PARD Poniard Pharmaceuticals (PARD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Poniard Pharmaceuticals Stock (OTCMKTS:PARD) 30 days 90 days 365 days Advanced Chart Get PARD alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume2,479 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington. Read More Receive PARD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poniard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PARD Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com PARD Stock Analysis - Frequently Asked Questions How do I buy shares of Poniard Pharmaceuticals? Shares of PARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Poniard Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Poniard Pharmaceuticals investors own include Plug Power (PLUG), Devon Energy (DVN), DOW (DOW), Chevron (CVX), Corteva (CTVA), Constellation Energy (CEG) and Brenmiller Energy (BNRG). Company Calendar Today7/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PARD CIK755806 Webwww.poniard.com Phone(206) 281-7001Fax650-583-3789Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.25 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (OTCMKTS:PARD) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poniard Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poniard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.